A phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions
Study of IDE196 in Patients with Solid Tumors
Sponsor: IDEAYA Biosciences
Enrolling: Male and Female Patients
IRB Number: AAAS4168
U.S. Govt. ID: NCT03947385
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety profile of IDE196 (an investigational drug), in enrolled subjects to find out if it is safe and possibly helpful in patients with certain cancers such as metastatic uveal melanoma, cervical cancer, lung cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, cutaneous melanoma or colorectal cancer or cancers with mutations in genes called GNAQ, GNA11, or PRKC fusion. The study may last for approximately 25 months and your participation will depend on how well you tolerate the study drug and your overall condition during the study.
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a solid tumor(s) that has either progressed following prior standard therapies? Yes No
Are you willing to possibly undergo biopsies during the study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162